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Abstract
Diffusion tensor imaging (DTI) and MR spectroscopic imaging (MRSI) provide greater sensitivity than conventional MRI to
detect diffuse alterations in normal appearing white matter (NAWM) of Multiple Sclerosis (MS) patients with different clinical
forms. Therefore, the goal of this study is to combine DTI and MRSI measurements to analyze the relation between diffusion
and metabolic markers, T2-weighted lesion load (T2-LL) and the patients clinical status. The sensitivity and specificity of
both methods were then compared in terms of MS clinical forms differentiation. MR examination was performed on 71 MS
patients (27 relapsing remitting (RR), 26 secondary progressive (SP) and 18 primary progressive (PP)) and 24 control subjects.
DTI and MRSI measurements were obtained from two identical regions of interest selected in left and right centrum
semioval (CSO) WM. DTI metrics and metabolic contents were significantly altered in MS patients with the exception of N-
acetyl-aspartate (NAA) and NAA/Choline (Cho) ratio in RR patients. Significant correlations were observed between diffusion
and metabolic measures to various degrees in every MS patients group. Most DTI metrics were significantly correlated with
the T2-LL while only NAA/Cr ratio was correlated in RR patients. A comparison analysis of MR methods efficiency
demonstrated a better sensitivity/specificity of DTI over MRSI. Nevertheless, NAA/Cr ratio could distinguish all MS and SP
patients groups from controls, while NAA/Cho ratio differentiated PP patients from controls. This study demonstrated that
diffusivity changes related to microstructural alterations were correlated with metabolic changes and provided a better
sensitivity to detect early changes, particularly in RR patients who are more subject to inflammatory processes. In contrast,
the better specificity of metabolic ratios to detect axonal damage and demyelination may provide a better index for
identification of PP patients.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease
of the central nervous system. Characterized by alternating episodes
of neurologic disability and recovery [1], this initial relapsing
remitting (RR) phase of the disease is frequently followed by a
secondary progressive course (SP) expressed by a steady neurolog-
ical deterioration without remission. Some other forms of MS
appear to follow a progressive course from the onset (primary
progressive (PP)) without obvious relapses and remissions of
neurological deficits [2]. MS pathogenesis implies complex
processes, including various degrees of reactive astrogliosis,
oligodendroglial loss, phagocytic activity, axonal pathology and
some remyelination [3], which lead to focal inflammatory and
demyelinating white matter (WM) lesions [4] and diffuse micro-
scopic alterations in normal appearing white matter (NAWM) [5].
Conventional magnetic resonance imaging (MRI) allows a
better diagnosis and therapeutic follow-up of MS patients. Typical
MRI measures of the disease burden in MS have demonstrated
modest correlations with the patients disability. Also known as the
‘‘clinico-radiological paradox’’ [6], this mismatch is probably due
to the insensitivity of T2-weighted MRI measures to detect subtle
histopathological alterations in NAWM. This argument has
contributed to the development of new quantitative MR methods
including MR spectroscopic imaging (MRSI) [7] and diffusion
tensor imaging (DTI) [8] that present better sensitivity and/or
specificity to characterize diffuse alterations in MS.
Based on the measurement of water molecules Brownian
motion, DTI has proved to be very sensitive to detect micro-
structural changes in the WM of MS patients [9]. In lesions,
previous studies have shown increased mean diffusivity (MD) and
decreased fractional anisotropy (FA) when compared with normal
WM of healthy controls. The highest MD values appear to be
found in non-enhanced T1-hypointense lesions while the lowest
FA values were found in contrast enhanced MS lesions [10–11].
These microstructural alterations are probably related to myelin
breakdown and/or axonal damage [9] that could be better
characterized by the measurement of the diffusion tensor axial (la)
and radial (lr) diffusivities [12–13].
Proton MRSI provides the spatial distribution of several
metabolites including N-acetylaspartate (NAA) [14], which is
associated with axonal/neuronal damage or dysfunction [15]).
While the creatine (Cr) signal provides an index of cell proliferation
by monitoring cellular energy metabolism, the choline (Cho) signal
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sensitive to demyelination and remyelination processes. In active
inflammatory MS lesions and NAWM, metabolic alterations
included increases in Cr and Cho content and variable decreases
of NAAconcentration. In contrast,NAAreductionwas more severe
in chronic non-enhancing lesions confirming its ability to detect
axonal damage [16]. Finally, these metabolic measures proved to be
better correlated with the patient clinical status than conventional
MRI [17].
Therefore, we first proposed in this study to analyze the relation
between microstructural changes and metabolic alterations,
measured by DTI and MRSI respectively, in the centrum
semioval (CSO) region of MS patients with different clinical
forms. Second, correlations between these MRI markers, the T2
lesion load (T2-LL), and the patient clinical status were analyzed
to better understand the underlying pathological processes and
their clinical expression. Third, DTI and MRSI methods were
compared in terms of sensitivity and specificity, for the detection of
pathological changes and the differentiation of MS clinical forms.
Materials and Methods
Subjects
Seventy-one patients (27 RR, 26 SP and 18 PP) with clinically
definite MS according to the McDonald’s criteria [18] were
included in this study (Table 1). All patients underwent a full
neurological examination performed by a neurologist, including
the measurement of their expended disability status scale (EDSS).
This work is part of an observational longitudinal study in which
medical therapy has been unchanged. Thus, only 22% of PP
patients versus 63% and 58% of RR and SP patients, respectively,
were under immune-modulating therapy. Twenty-four volunteers
with no history of neurological disorders served as control subjects.
Local ethical committee approval and written informed consents
were obtained from all patients and control subjects prior to study
initiation.
MRI Protocol
All patients and control subjects underwent MR examination
using a 1.5 Tesla MR system (Sonata Siemens, Erlangen, Germany)
and an 8 elements phased-array head-coil. Conventional MRI
protocol comprised a 3 dimensional T1-weighted (magnetization
preparedrapidgradientecho-MPRAGE)sequencewithandwithout
gadolinium injection (repetition time/echo time/time for inver-
sion [TR/TE/TI]=1970/3.93/1100 ms; flip angle=15u;m a t r i x
size=2566256; field of view [FOV]=2566256 mm; slice thick-
ness=1 mm;voxelsize=16161 mm;acquisitiontime=4.62 min),
aTurboSpin-Echo(TSE)withprotondensity(PD)andT2-weighted
contrasts (TR/TE1/TE2=3020/12/85 ms; flip angle=180u;m a -
trix size=1926256; FOV=2406240 mm; slice thickness=3 mm;
voxel size=0.960.963 mm; acquisition time=4.55 min) and a
fluid-attenuated inversion recovery (FLAIR) sequence (TR/TE/
TI=8000/105/2200 ms; flip angle=150u; matrix size=1926256;
FOV=2406240 mm; slice thickness=3 mm; voxel size=0.96
0.963 mm; acquisition time=4.57 min).
A spin-echo echo-planar DTI sequence was performed with the
following imaging parameters (TR=6900 ms; TE=86 ms; matrix
size=96696; FOV=2406240 mm; slice thickness=2.5 mm;
voxel size=2.562.562.5 mm; acquisition time=6.67 min) to
acquire 51 axial slices oriented along the anterior commissure-
posterior commissure (AC-PC). Diffusion gradients were applied
along 24 non-collinear directions with a b factor of 1000 s/mm
2.
The b0 image was acquired four times to increase signal to noise
ratio.
MRSI acquisition consisted in one slice placed above the corpus
callosum along the AC-PC axis, encompassing the centrum
semioval region. A PRESS sequence (TR=1690 ms; TE=
135 ms) was used to select a VOI of 1061061.5 cm during the
acquisition of 24624 (interpolated to 32632) phase-encodings
over a FOV of 2406240 mm.
Data Analysis and Post-Processing
All image post-processing was performed on a Windows PC
workstation. For correlation purpose between metabolic and
diffusion measures, two identical regions of interest (ROI) were
selected in left and right CSO areas from MRSI and DTI data.
First, two ROIs of 662 voxels were selected from the MRSI.
MR signals obtained from the 24 voxels were automatically
corrected for phase and frequency shift using residual water signal
and summed to produce a single MR signal for each subject.
Water signal was suppressed by a Singular Value Decomposition
of a Hankel matrix using Lanczos algorithm (HLSVD) using 25
components on a frequency window from -2.5 to 0.46 ppm.
Background signal from lipids, macromolecules and lineshape
distortions were handled using a subtract method of first temporal
points optimized to 5 ms. Signal amplitude of metabolites was
finally estimated by the QUEST algorithm [19] with prior
information of NAA, Cho and Cr simulated by NMRScope [20].
Metabolic ratios were calculated, and concentrations obtained
using a calibration on a reference phantom of known concentra-
tions [21].
Second, the ROIs previously selected from MRSI were
positioned on diffusion maps based on their absolute coordinates.
From each ROI corresponding to 156565 voxels of DTI images,
Table 1. Demographics and group characteristics.
Controls RR SP PP All-MS
Number of subjects 24 27 26 18 71
Age [years] 36.0 (9.5) 35.1 (7.3) 41.7 (5.1) 41.2 (6.5) 39.1 (7.0)
Disease duration [years] - 6.9 (4.2) 14.3 (6.1) 6.7 (3.1) 9.5 (6.0)
Median EDSS (range) - 2 (0.0–6.0) 4.8 (2.5–7.0) 4.0 (2.5–7.0) 4.0 (0.0–7.0)
ROI T2-LL (%) - 19.7 (11.3) 28.9 (15.2) 39.0 (20.6) 28.0 (17.1)
Brain T2-LL (%) - 0.14(0.09) 0.29(0.24) 0.61(0.33) 0.60(0.41)
Values are expressed as mean (Standard deviation).
RR: relapsing remitting; SP: secondary progressive; PP: primary progressive; EDSS: expanded disability status scale; ROI T2-LL: T2-lesion load corresponding to the lesion
volume measured within the region of interest (ROI); Brain T2-LL: T2-lesion load corresponding to the lesion volume measured in the whole brain.
doi:10.1371/journal.pone.0032525.t001
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diffusion metrics. MedINRIA software (http://www-sop.inria.fr/
asclepios/software/MedINRIA/) was used to calculate and
visualize FA, MD, la( l1) and lr (mean of l2 and l3) maps.
The ROI T2-LL value was obtained by measuring the volume
of the manually segmented T2-lesions inside the ROI. The brain
T2-lesion volume measurements were extracted from co-registered
T1-, T2-, PD-weighted and FLAIR images, using an automatic
segmentation algorithm in the SEPINRIA software [22]. The
lesion masks were validated by an experienced neurologist before
calculating the lesion volume. ROI and brain T2-lesion volumes
were then normalized by the ROI volume and the subject
intracranial volume, respectively.
Statistical Analysis
Statistical analysis of diffusion and metabolic results was
performed using Data Analysis and Statistical Software (STATA,
Version 9.2, StataCorp, Texas, USA). Metabolic concentrations
and ratios, and diffusion values were compared between patients
and controls using a One-Way ANOVA test. Bonferroni
correction was used to perform post-hoc multiple comparisons.
Spearman correlation test was applied to assess the relationship,
first between diffusion metrics and metabolic concentrations and
ratios (corrected for ROI T2-LL), and second between DTI and
MRS measures along with T2-LL and EDSS values. Correlations
were not corrected for multiple comparisons. Values were
considered significant at p,0.05.
Comparison of DTI and MRSI efficiency to differentiate MS
patients from control subjects was performed using a receiver
operating characteristic (ROC) curve analysis. Sensitivity and
specificity of the most significant DTI metrics (MD, lr) were
compared to those of MRSI (NAA/Cr, NAA/Cho) by analyzing
the areas under ROC curves (AUC) in different clinical forms
(RR, SP, PP) and in the all-MS patients group versus control
subjects.
Results
Diffusion measures
DTI-derived parameters measured in the CSO regions showed
significant alterations in every MS patients group (Table 2).
Increases of both axial and radial diffusivity values, with lr
changes (21.0%) being twice as much higher as la (11.2%) in all-
MS patients group, resulted in highly significant MD increases and
FA reductions. When comparing SP to RR patients, FA values
were significantly decreased (p,0.01) whereas MD (p,0.01), la
(p,0.05) and lr( p ,0.001) values were increased. In contrast, no
significant changes were detected between PP and RR patients.
Metabolic measures
Quantification of metabolite concentrations showed a signifi-
cant decrease of NAA concentration, and increases of Cr and Cho
concentrations, in the all-MS patients group compared to controls
(Table 2). While there were no significant changes in RR patients
compared to controls, NAA concentrations were significantly
reduced in SP and PP patients. Cr concentrations increased
significantly only in SP patients. The estimation of these
concentrations resulted in significant decreases of NAA/Cr and
NAA/Cho ratios in the all-MS patients group as well as in SP and
PP patients relative to controls. NAA/Cr ratios were also
significantly lower in RR patients compared to controls.
Relationship between diffusion and metabolic measures
and T2-lesion load
Diffusion parameters showed significant correlations with NAA
concentrations and NAA/Cr ratios in MS patients, either pooled
all together or separated by clinical forms (RR, SP and PP)
(Table 3). Interestingly, NAA was only significantly correlated with
the axial diffusivity in RR patients. Also, NAA/Cho ratios were
significantly correlated with FA values in PP patients (r=0.69,
p,0.01).
In the all-MS patients group, significant correlations were
observed between the ROI T2-LL and FA (r=20.29; p,0.05),
MD, la, lr, NAA concentration (r=20.31; p,0.01) and NAA/
Cr ratio (Table 4). When comparing clinical forms, correlations
between the ROI T2-LL and MD, axial and radial diffusivities
were the most significant in PP patients. In contrast, the NAA/Cr
ratio and the NAA content were not correlated with the ROI T2-
LL in any patients groups, with the exception of the NAA/Cr ratio
in RR patients. To illustrate these results, the correlations between
radial diffusivity and NAA/Cr ratio with the ROI T2-LL were
displayed in Fig. 1 for RR, PP and all-MS patient groups.
Regarding the association with the patients disability measured
by the EDSS, both diffusion (FA: r=20.34, p,0.01; MD:
Table 2. Diffusion and metabolic measures in MS patients and control subjects groups.
Controls RR SP PP All-MS
MD 0.7160.03 0.7960.05*** 0.8660.10*** 0.8360.09*** 0.8360.09***
FA 0.4060.02 0.3860.03* 0.3560.03*** 0.3660.04*** 0.3660.04***
la 1.0360.04 1.1260.05*** 1.1860.10*** 1.1660.10*** 1.1560.09***
lr 0.5560.03 0.6360.05*** 0.7060.10*** 0.6760.09*** 0.6760.09***
NAA 11.5261.01 11.1260.76 10.1961.29*** 10.2061.25*** 10.5461.18***
Cho 1.5260.17 1.6160.17 1.6660.35 1.6660.20 1.6460.25*
Cr 9.2660.90 9.6060.80 9.8960.93* 9.6760.84 9.7260.85*
NAA/Cr 2.5460.15 2.3760.18** 2.1060.25*** 2.1560.18*** 2.2260.24***
NAA/Cho 2.7260.28 2.4960.31 2.2860.50*** 2.2160.30*** 2.3460.40***
Values (Mean 6 SD) of mean diffusion (MD), fraction of anisotropy (FA), axial (la) and radial (lr) diffusivities, N-acetylaspartate (NAA), choline (Cho) and creatine (Cr)
(*p,0.05; **p,0.01; ***p,0.001 when compared to controls). RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.
doi:10.1371/journal.pone.0032525.t002
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r=20.36, p,0.01) measures were moderately correlated in the
all-MS patient group. EDSS was also correlated with FA values
(r=20.52; p,0.05) and several metabolic measures (NAA/Cho:
r=20.50; p,0.05; Cho/Cr: r=0.48; p,0.05; Cho: r=0.55;
p,0.05) in PP patients. No significant correlations were found
between EDSS and T2-LL (brain or ROI).
Analysis of ROC Curves
ROC analysis was performed to compare the efficiency of
diffusion and metabolic markers to differentiate controls from MS
patients, taken as one group or separated by clinical forms (Fig. 2).
If the overall best sensitivity/specificity was obtained by MD and
lr measures, the NAA/Cr ratio was also efficient to distinguish all-
MS and SP patient groups from controls. NAA/Cho ratio also
helped to better differentiate PP patients from controls (Table 5).
However, the metabolic ratios of NAA/Cr and NAA/Cho were
significantly less efficient than diffusion metrics to distinguish RR
patients from controls.
Discussion
In this study, diffusion and metabolic parameters were
measured in the centrum semioval WM region of MS patients
with different clinical forms in order to test first, their inter-
relations and second, their correlations with the T2-LL and the
patient clinical disability. Both MR modalities provided several
metrics that were significantly modified by the pathological
processes occurring in MS. Further, these diffusion and metabolic
changes were significantly correlated highlighting a relation
between microstructural and metabolic alterations.
If all diffusion parameters presented a high sensitivity to detect
alterations in any clinical form, and even in the less severe RR
form, one can notice the greater change of lr compared to la. As
reported in animal models of MS [23], these changes may reflect
greater damage in myelin [12] than in axons [24–25]. Indeed, the
correlations observed between the diffusion metrics and the ROI
T2-LL highlighted a link between local injuries due to inflamma-
tory and/or demyelinating lesions [26] and microstructural
alterations. Furthermore, these correlations were more significant
in RR and PP patients that are more subject to inflammatory
processes than SP patients.
Metabolic alterations found in MS patients included increases of
Cr and Cho concentrations and reduction of NAA content leading
to decreased NAA/Cr and NAA/Cho ratios. In agreement with
previous studies [16], these findings showed that NAWM is subject
to several tissue restructuring. While the reduction of NAA, a
compound present in neurons [27], may reflect axonal damage, Cr
increase was reported as a putative marker of cell proliferation that
is consistent with oligodendrocytes remyelination and astrocytic
gliosis [28]. In contrast to diffusion, metabolic measures showed no
significant correlation with the ROI T2-LL, except for the NAA/
Cr ratio in RR patients. These findings may suggest that NAA
changes are less sensitive to inflammatory processes occurring in
T2-lesions but might be more specific to irreversible axonal
damage. This hypothesis was furthermore highlighted by the
correlation found between NAA concentration and axial diffusivity
in RR patients. Alternatively, the correlations obtained between
NAA/Cr ratios and T2-LL values were only significant in RR
patients reflecting the association of subtle axonal abnormalities
and cell proliferation, probably due to indirect effects of
inflammation [29].
Correlations between diffusion metrics and NAA/Cr ratios
were significant in every MS patient group, especially in PP
patients. Such correlations between reduced NAA values and
increased MD were previously reported in the WM of PP patients
[30]. Also, Oh et al. [31] reported moderate correlations between
radial diffusivity and NAA/Cr ratio measured in the corpus
callosum of MS patients. Thus, these correlations observed
between diffusion metrics and NAA/Cr ratios highlighted a
Table 4. Correlation rates (r) between diffusion and
metabolic measures and the ROI T2-LL in different groups of
MS patients.
ROI T2-LL
RR SP PP All-MS
MD 0.62*** 0.42* 0.71*** 0.58***
la 0.56** 0.50** 0.72*** 0.61***
lr 0.52** 0.39* 0.68** 0.54***
NAA/Cr 20.40* 20.08 20.33 20.37**
Correlation significance (*p,0.05; **p,0.01; ***p,0.001).
ROI T2-LL: T2-lesion load corresponding to the lesion volume within the region
of interest, MD: mean diffusion, FA: fraction of anisotropy, la: axial diffusivity,
lr: radial diffusivity, NAA: N-acetylaspartate, Cr: creatine, RR: relapsing remitting;
SP: secondary progressive; PP: primary progressive.
doi:10.1371/journal.pone.0032525.t004
Table 3. Correlation rates (r) between diffusion and metabolic measures corrected for T2-lesion load in different groups of MS
patients.
NAA/Cr NAA
RR SP PP All-MS RR SP PP All-MS
MD 20.60*** 20.53** 20.56* 20.61*** 20.37 20.53** 20.57* 20.57***
FA 0.54** 0.64*** 0.46 0.58*** 0.29 0.50** 0.67** 0.56***
la 20.52** 20.47* 20.55* 20.57*** 20.39* 20.50** 20.41 20.51***
lr 20.60*** 20.55** 20.54* 20.61*** 20.35 20.54** 20.63** 20.59***
Correlation coefficient (*p,0.05; **p,0.01; ***p,0.001).
MD: Mean diffusion, FA: fraction of anisotropy, la: axial diffusivity, lr: radial diffusivity, NAA: N-acetylaspartate, Cr: creatine, RR: relapsing remitting; SP: secondary
progressive; PP: primary progressive.
doi:10.1371/journal.pone.0032525.t003
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that could both be the resultant of the inflammatory cascade and
demyelinating processes, and/or axonal damages. If the degree of
correlation varied with the patient clinical status, the most
significant result was found in PP patients where both degenerative
and inflammatory mechanisms are believed to occur simulta-
neously [32].
In contrast, correlations measured between diffusion metrics
and NAA were only significant in the progressive forms of MS (SP
and PP), and particularly in SP patients. These findings probably
revealed the better specificity of NAA to reflect chronic lesions and
the underlying axonal loss. This interpretation is reinforced by the
lack of correlation in RR patients where NAA changes may
represent reversible metabolic dysfunctions or axonal integrity
rather than irreversible axonal transection [26]. RR patients are
probably more subject to reversible inflammatory and remyelinat-
ing mechanisms according to their best response to anti-
inflammatory treatments [33–35]. Indeed, the lack of significant
NAA changes observed in our RR group could result from the
immune-modulating medication prescribed to most of these
patients.
Significant correlations between FA and NAA/Cho ratio were
also observed in PP patients suggesting that the NAA/Cho ratio
could constitute a specific index of primary pathological
mechanisms including demyelination and axonal damage [36].
Indeed, the ROC analysis showed that the NAA/Cho ratio was as
efficient as diffusion metrics and NAA/Cr ratio, to differentiate PP
patients from control subjects. Nevertheless, MD and lr measures
were significantly more sensitive than any metabolic ratios to
differentiate RR patients from controls, suggesting that diffusion
metrics constitute the most sensitive indicators of early inflamma-
tion-related structural damage in NAWM.
In conclusion, the analysis of the relation between microstruc-
tural damage (as detected by DTI) and metabolic alterations
(as detected by MRSI) demonstrated the better sensitivity of
diffusion relative to metabolic markers. This sensitivity to early
Figure 1. Correlations between radial diffusivity (lr) and NAA/Cr ratio with the ROI T2-LL in RR, PP and all-MS patient groups.
(NS=Not significant).
doi:10.1371/journal.pone.0032525.g001
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by the correlation observed between diffusion markers and the T2-
LL. In contrast, metabolic ratios such as NAA/Cr or NAA/Cho
may constitute efficient markers, due to their better specificity, to
differentiate progressive forms where neurodegeneration is more
pronounced. Therefore, the complementary sensitivity of DTI
with the specificity of MRSI to detect early brain microstructural
changes along with diffuse metabolic alterations may provide
a better understanding of the various pathological processes
interactions.
Figure 2. ROC curves of the mean diffusion (MD), axial (la) and radial (lr) diffusivities, NAA/Cho and NAA/Cr ratios in RR (A), SP (B),
PP (C) and all-MS patient groups (D).
doi:10.1371/journal.pone.0032525.g002
Table 5. Areas under ROC curves analysis of DTI and MRSI derived measures in different groups of MS patients.
RR SP PP All-MS
MD vs. NAA/Cr 0.98.0.78** 0.96<0.96 0.92<0.96 0.96<0.89
MD vs. NAA/Cho 0.98.0.72*** 0.96.0.78* 0.92<0.89 0.96.0.79**
lr vs. NAA/Cr 0.95.0.78* 0.96<0.96 0.93<0.96 0.95<0.89
lr vs. NAA/Cho 0.95.0.72** 0.96.0.78* 0.93<0.89 0.95.0.79**
Statistical significance (*p,0.05; **p,0.01; ***p,0.001) when comparing areas under ROC curves (AUC) of the following MR metrics: MD: mean diffusivity, lr: radial
diffusivity, NAA: N-acetylaspartate, Cr: creatine, RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.
doi:10.1371/journal.pone.0032525.t005
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